128 related articles for article (PubMed ID: 38318754)
1. Substituting Poly(ethylene glycol) Lipids with Poly(2-ethyl-2-oxazoline) Lipids Improves Lipid Nanoparticle Repeat Dosing.
Sanchez AJDS; Loughrey D; Echeverri ES; Huayamares SG; Radmand A; Paunovska K; Hatit M; Tiegreen KE; Santangelo PJ; Dahlman JE
Adv Healthc Mater; 2024 Feb; ():e2304033. PubMed ID: 38318754
[TBL] [Abstract][Full Text] [Related]
2. Tailored Monoacyl Poly(2-oxazoline)- and Poly(2-oxazine)-Lipids as PEG-Lipid Alternatives for Stabilization and Delivery of mRNA-Lipid Nanoparticles.
He X; Payne TJ; Takanashi A; Fang Y; Kerai SD; Morrow JP; Al-Wassiti H; Pouton CW; Kempe K
Biomacromolecules; 2024 Jun; ():. PubMed ID: 38918933
[TBL] [Abstract][Full Text] [Related]
3. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury.
Waggoner LE; Miyasaki KF; Kwon EJ
Biomater Sci; 2023 Jun; 11(12):4238-4253. PubMed ID: 36987922
[TBL] [Abstract][Full Text] [Related]
4. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production.
Suzuki T; Suzuki Y; Hihara T; Kubara K; Kondo K; Hyodo K; Yamazaki K; Ishida T; Ishihara H
Int J Pharm; 2020 Oct; 588():119792. PubMed ID: 32827675
[TBL] [Abstract][Full Text] [Related]
5. Visible Light Conjugation with Triazolinediones as a Route to Degradable Poly(ethylene glycol)-Lipids for mRNA Lipid Nanoparticle Formulation.
Golba B; Soete M; Zhong Z; Sanders N; Du Prez FE; Houck HA; De Geest BG
Angew Chem Int Ed Engl; 2023 Jun; 62(23):e202301102. PubMed ID: 36896730
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model.
Wong P; Li L; Chea J; Delgado MK; Poku E; Szpikowska B; Bowles N; Minnix M; Colcher D; Wong JYC; Shively JE; Yazaki PJ
Cancer Biother Radiopharm; 2017 Sep; 32(7):247-257. PubMed ID: 28910151
[TBL] [Abstract][Full Text] [Related]
7. Engineering LNPs with polysarcosine lipids for mRNA delivery.
Kang DD; Hou X; Wang L; Xue Y; Li H; Zhong Y; Wang S; Deng B; McComb DW; Dong Y
Bioact Mater; 2024 Jul; 37():86-93. PubMed ID: 38523704
[TBL] [Abstract][Full Text] [Related]
8. Development of Lipid Nanoparticle Formulation for the Repeated Administration of mRNA Therapeutics.
Lee Y; Jeong M; Lee G; Park J; Jung H; Im S; Lee H
Biomater Res; 2024; 28():0017. PubMed ID: 38779139
[TBL] [Abstract][Full Text] [Related]
9. Design of abiotic polymer ligand-decorated lipid nanoparticles for effective neutralization of target toxins in the blood.
Koide H; Yamauchi I; Hoshino Y; Yasuno G; Okamoto T; Akashi S; Saito K; Oku N; Asai T
Biomater Sci; 2021 Aug; 9(16):5588-5598. PubMed ID: 34241600
[TBL] [Abstract][Full Text] [Related]
10. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs.
Lokugamage MP; Vanover D; Beyersdorf J; Hatit MZC; Rotolo L; Echeverri ES; Peck HE; Ni H; Yoon JK; Kim Y; Santangelo PJ; Dahlman JE
Nat Biomed Eng; 2021 Sep; 5(9):1059-1068. PubMed ID: 34616046
[TBL] [Abstract][Full Text] [Related]
11. Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method.
Berger M; Degey M; Leblond Chain J; Maquoi E; Evrard B; Lechanteur A; Piel G
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839919
[TBL] [Abstract][Full Text] [Related]
12. Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing.
Sarode A; Fan Y; Byrnes AE; Hammel M; Hura GL; Fu Y; Kou P; Hu C; Hinz FI; Roberts J; Koenig SG; Nagapudi K; Hoogenraad CC; Chen T; Leung D; Yen CW
Nanoscale Adv; 2022 May; 4(9):2107-2123. PubMed ID: 36133441
[TBL] [Abstract][Full Text] [Related]
13. Elucidation of lipid nanoparticle surface structure in mRNA vaccines.
Wang MM; Wappelhorst CN; Jensen EL; Chi YT; Rouse JC; Zou Q
Sci Rep; 2023 Oct; 13(1):16744. PubMed ID: 37798336
[TBL] [Abstract][Full Text] [Related]
14. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
15. Hydrophobic Domain Structure of Linear-Dendritic Poly(ethylene glycol) Lipids Affects RNA Delivery of Lipid Nanoparticles.
Zhou K; Johnson LT; Xiong H; Barrios S; Minnig JT; Yan Y; Abram B; Yu X; Siegwart DJ
Mol Pharm; 2020 May; 17(5):1575-1585. PubMed ID: 32267707
[TBL] [Abstract][Full Text] [Related]
16. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
17. Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
Chen S; Tam YY; Lin PJ; Leung AK; Tam YK; Cullis PR
J Control Release; 2014 Dec; 196():106-12. PubMed ID: 25285610
[TBL] [Abstract][Full Text] [Related]
18. Effect of lipid composition on RNA-Lipid nanoparticle properties and their sensitivity to thin-film freezing and drying.
AboulFotouh K; Southard B; Dao HM; Xu H; Moon C; Williams Iii RO; Cui Z
Int J Pharm; 2024 Jan; 650():123688. PubMed ID: 38070660
[TBL] [Abstract][Full Text] [Related]
19. Fluorinated Lipid Nanoparticles for Enhancing mRNA Delivery Efficiency.
Zhang H; Meng C; Yi X; Han J; Wang J; Liu F; Ling Q; Li H; Gu Z
ACS Nano; 2024 Mar; 18(11):7825-7836. PubMed ID: 38452271
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of antitumor efficacy of folate-poly(2-ethyl-2-oxazoline)-distearoyl phosphatidyl ethanolamine based liposome.
Wang X; Li Y; Wang D; Wang X; Yuan W; Zhao W; Xia G
Pharm Dev Technol; 2021 Jan; 26(1):110-118. PubMed ID: 33104406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
